Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice

被引:69
作者
Kelly, EP [1 ]
Greene, JJ
King, AD
Innis, BL
机构
[1] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Virus Dis, Washington, DC 20307 USA
[2] Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA
关键词
dengue virus; purified envelope protein; recombinant protein; baculovirus; vaccine development;
D O I
10.1016/S0264-410X(00)00032-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The full-length dengue 2 virus envelope glycoprotein (Egp) was expressed in insect cells by recombinant (r) baculovirus and found to form multimeric aggregates that were recovered in the void volume of gel filtration columns and by ultracentrifugation. An immunoblot confirmed that rEgp aggregrates disrupted with SDS sample buffer released a monomeric form that migrated with a molecular weight similar to native dengue 2 virus Egp on polyacrylamide gels. The rEpp aggregates reacted strongly with a panel of monoclonal antibodies specific for the native Egp and which identify critical structural and functional epitopes. The rEgp aggregates were purified by ultracentrifugation through 30% sucrose, and were shown to be the major protein band on a polyacrylamide gel and corresponding immunoblot. Purified rEgp aggregates in combination with aluminum hydroxide induced high titer neutralizing antibodies in adult mice. The generation of full-length dengue 2 rEgp aggregates in insect cells facilitated development of a simple, effective procedure for purification of the recombinant protein: and represents a good approach for producing highly immunogenic dengue 2 rEgp as a component of a subunit vaccine. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2549 / 2559
页数:11
相关论文
共 53 条
[31]   USE OF RECOMBINANT FUSION PROTEINS AND MONOCLONAL-ANTIBODIES TO DEFINE LINEAR AND DISCONTINUOUS ANTIGENIC SITES ON THE DENGUE VIRUS ENVELOPE GLYCOPROTEIN [J].
MEGRET, F ;
HUGNOT, JP ;
FALCONAR, A ;
GENTRY, MK ;
MORENS, DM ;
MURRAY, JM ;
SCHLESINGER, JJ ;
WRIGHT, PJ ;
YOUNG, P ;
VANREGENMORTEL, MHV ;
DEUBEL, V .
VIROLOGY, 1992, 187 (02) :480-491
[32]   CARBOXY-TERMINALLY TRUNCATED DENGUE VIRUS ENVELOPE GLYCOPROTEINS EXPRESSED ON THE CELL-SURFACE AND SECRETED EXTRACELLULARLY EXHIBIT INCREASED IMMUNOGENICITY IN MICE [J].
MEN, R ;
BRAY, M ;
LAI, CJ .
JOURNAL OF VIROLOGY, 1991, 65 (03) :1400-1407
[33]   ISCOM, A NOVEL STRUCTURE FOR ANTIGENIC PRESENTATION OF MEMBRANE-PROTEINS FROM ENVELOPED VIRUSES [J].
MOREIN, B ;
SUNDQUIST, B ;
HOGLUND, S ;
DALSGAARD, K ;
OSTERHAUS, A .
NATURE, 1984, 308 (5958) :457-460
[34]  
MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
[35]   HEPATITIS-B VIRUS SURFACE-ANTIGEN (HBSAG) AS CARRIER FOR SYNTHETIC PEPTIDES HAVING AN ATTACHED HYDROPHOBIC TAIL [J].
NEURATH, AR ;
STRICK, N ;
GIRARD, M .
MOLECULAR IMMUNOLOGY, 1989, 26 (01) :53-62
[36]   RECOMBINANT VACCINIA VIRUS PRODUCING THE PRM AND E-PROTEINS OF YELLOW-FEVER VIRUS PROTECTS MICE FROM LETHAL YELLOW-FEVER ENCEPHALITIS [J].
PINCUS, S ;
MASON, PW ;
KONISHI, E ;
FONSECA, BAL ;
SHOPE, RE ;
RICE, CM ;
PAOLETTI, E .
VIROLOGY, 1992, 187 (01) :290-297
[37]   Development of a purified, inactivated, dengue-2 virus vaccine prototype in vero cells: Immunogenicity and protection in mice and rhesus monkeys [J].
Putnak, R ;
Barvir, DA ;
Burrous, JM ;
Dubois, DR ;
DAndrea, VM ;
Hoke, CH ;
Sadoff, JC ;
Eckels, KH .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1176-1184
[38]   DENGUE-1 VIRUS ENVELOPE GLYCOPROTEIN GENE EXPRESSED IN RECOMBINANT BACULOVIRUS ELICITS VIRUS-NEUTRALIZING ANTIBODY IN MICE AND PROTECTS THEM FROM VIRUS CHALLENGE [J].
PUTNAK, R ;
FEIGHNY, R ;
BURROUS, J ;
COCHRAN, M ;
HACKETT, C ;
SMITH, G ;
HOKE, C .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1991, 45 (02) :159-167
[39]   Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas [J].
RicoHesse, R ;
Harrison, LM ;
Salas, RA ;
Tovar, D ;
Nisalak, A ;
Ramos, C ;
Boshell, J ;
deMesa, MTR ;
Nogueira, RMR ;
daRosa, AT .
VIROLOGY, 1997, 230 (02) :244-251
[40]  
RUSSELL PK, 1967, J IMMUNOL, V99, P285